Sign-ons, declarations and joint statements
EATG has been partnering up with NGOs, international organisations and alliances to support causes that are important or interesting for the communities of people living with or affected by HIV and co-morbidities. This list contains documents, declarations and statements that EATG has co-signed or endorsed since 2015:
29.01.2015 – ITPC and TAG
Rejection of sofosbuvir patent in India and voluntary license scheme of Gilead Sciences.
We are at a critical juncture, where curative treatment for hepatitis C is available on the market but virtually inaccessible to most of the world’s people living with HCV. A recent decision by India’s Patent Office rejecting one of Gilead’s key patents for sofosbuvir is an important step to potentially open up more generic competition outside the restrictive licenses. But Gilead is using every trick in the book to get the decision reversed, including lobbying the Indian Government. Help us tell Gilead to drop their case and do the right thing to promote global treatment access.
16.02.2015 – TB Europe Coalition
Appeal to EU Commissioner Andriukaitis to take leadership in tuberculosis awareness and treatment
The letter welcomes Andriukaitis’ appointment as Commissioner and urges him to champion TB in Europe. The letter requests that the Commissioner uses his presence at the upcoming Ministerial Meeting on TB, hosted by Latvia, to ensure cooperation between the EC, member states and neighbouring countries and to also let us know about what plans the EC have to ensure the meeting is a success.
01.01.2015 – EATG
Community manifesto: We need PrEP now
Open letter from European HIV & LGBT community organisations and other concerned Europeans to pharmaceutical industries, European and national institutions on the need to introduce PrEP as soon as possible.
15.04.2015 – EATG and EU HIV Civil Society Forum members
Public Health Protection Law – Protest against the 2015 amendment, Introduction of mandatory HIV testing of certain at-risk populations
17.06.2015 – PICUM and EPHA
To the meeting of the minsters of health before the EPSCO Council June 2015 regarding the health dimension of the European agenda of migration
Emphasising the need for access to treatment and prevention services for undocumented migrants and individuals with an unclear legal status.
15.09.2015 – EATG and EU HIV Civil Society Forum
Joint letter for an integrated policy framework on HIV, TB and HCV
Civil society representatives call the EU to renew the EU policy framework by integrating HIV, viral hepatitis and tuberculosis into one overarching policy.
01.11.2015 – EuroPrEP and civil society organisations
Facilitating access to PrEP in Europe through reduced pricing
Current prevention options in Europe include abstinence, condoms, and monogamy. Better access to treatment for people living with HIV means that they are not infectious to others. But altogether these haven’t solved the problem and we still have a raging HIV epidemic in Europe and beyond.
18.11.2015 – EU HIV Civil Society Forum
Importance of the consolidated EU position for the UNGASS 2016 outcome document Letters to the Dutch government in preparation for the Dutch EU presidency, EU high level group on drugs about the EU position at UNGASS on Drugs in 2016.
17.02.2016 – Hepatitis B&C Public Policy Association
The signatories of the declaration, gathered in Brussels on the occasion of the first European Union HCV Policy Summit, on 17 February 2016, are committed to the elimination of hepatitis C in Europe.
19.02.2016 – EATG EU HIV CSF
Investigation of MSM living with HIV STI diagnosis is seen as discriminatory persecution
Pan-European Networks of communities of people living with and affected by HIV, doctors and scientists call upon the Government of the Czech Republic to immediately stop the Prague Public Health Authority’s persecution and intimidation of people living with HIV, and to return to evidence based and proven practices in HIV prevention, testing and care in the Czech Republic.
31.03.2016 – European Alliance for Responsible R&D and Affordable Medicines
Joint declaration for a research and development system that is driven by public health needs and delivers medicines that are universally accessible and affordable
In Europe and worldwide, the price of new medicines is rising year on year, especially where there is no therapeutic alternative. As a result, treatment for life-threatening infections and diseases, like HIV/AIDS, cancer and hepatitis C, are increasingly unaffordable for both individuals and national health systems. This is the result of an ineffective and costly research and development (R&D) system that rewards new medicines with fixed-term monopolies (patents) and encourages unaffordable price setting.
17.04.2016 – EPHA and NGOs
Civil society urges Member States to support the Dutch EU Presidency’s vision on access to affordable medicines
We strongly support the Dutch European Union (EU) Presidency’s critique of the current over-protection and misuse of intellectual property and related rights for pharmaceuticals, and its goal to better balance the reward for innovation against the assurance of affordability of medicines.
31.04.2016 – AIDES and NGOs
Brussels Appeal for Access to PrEP
At a time when so many therapeutic milestones regarding HIV/AIDS have been achieved and when, for the first time, the end of the epidemic is possible if we combine prevention, early diagnosis and immediate treatment, it should be the responsibility of health stakeholders to implement all the tools available, including PrEP, to reach the goal of a world without AIDS.
12.09.2016 – TB Europe coalition
CSO letter to 2017 Estonian Presidency on tuberculosis
The region of Eastern Europe and Central Asia (EECA) is home to the fastest growing HIV and HCV epidemics and the highest rates of multi-drug resistant TB (MDR-TB) in the world. According to WHO, 2013 there were 80% more new HIV cases in Europe compared to 20041. UNAIDS considers the EECA as the only region in the world where HIV prevalence continues to grow2. At the same time, in many countries of the European region, rates of MDR-TB3 are alarming. EECA has the world’s highest rates of new TB patients with MDR-TB4, which has become an epidemic on its own, and TB is among one of the leading causes of death of HIV positive people in the region. Moreover, in many countries hepatitis C prevalence nears 80% in people who use drugs5 and the number of related deaths rises yearly.
30.09.2016 – European Alliance for Responsible R&D and Affordable Medicines
Open letter to the European Commission on the follow-up of the June 2016 EU Council Conclusions on “Strengthening the Balance in the Pharmaceutical Systems in the EU”
Civil society organisations urge the EU Health Ministers and the European Commission to undertake a much-needed research on the current models of research and development, and an in-depth evaluation of the impact of IP-related incentives. However, we are concerned about a lack of transparency and a lack of a balanced stakeholder involvement in the process.
03.10.2016 – Universities Allied for Essential Medicines
Open letter to the candidates for Director-General of the World Health Organization: Will you support an R&D agreement that puts patient needs at the centre of R&D?
We would like to invite the candidates to take a clear position on the future of WHO’s work in supporting a patient-centred R&D system.
09.08.2017 – TAG
Research on TB for pregnant women
Call initiated by the Treatment Action Group (US) for supporting TB research for pregnant women that is addressed to the Task Force on Research Specific to Pregnant and Lactating Women (PRGLAC). This is a US body addressing gaps in knowledge and research on safe and effective therapies for pregnant women and lactating women. It will have repercussion out on the research community beyond the US.
11.08.2017 – MSF
Request for the review of R&D incentives
In an open letter and open submission, thirty-three civil society organisations have called on the European Commission to abolish the supplementary protection certificates (SPC) mechanism and to stop encouraging the inclusion of SPCs – or similar mechanisms, such as patent term extensions – in free trade agreements with other countries.
03.10.2017 – ILGA
Speaking up against the harassment of LGBTI persons in Azerbaijan
Human rights organisations are calling on international institutions to put their human rights mandates into practice. We urge them to use all possible mechanisms available to strongly condemn the situation in Azerbaijan, such as public statements and bilateral diplomacy.
06.10.2017 – EPHA
Sustainable Development Goals should be reflected in EU trade policy
Civil society organisations call on the European Commission to design and implement a responsible trade policy which ensures health sustainability, enables public health action on health security threats, and mainstreams the EU commitments under the UN Sustainable Development Goals (SDGs). This is in line with the obligation in the EU treaties to ensure a high level of health protection in all EU policy areas (TFEU article 168).
09.10.2017 – EATG and alliance of civil society organisations
Testing statement on most affected populations
“We recognise that European Testing Week 2017 marks a significant step up in advocacy and action to challenge existing barriers to safe voluntary testing, both real and perceived, and to truly ensure nobody is left behind. Building on this unique opportunity, we are pleased to stand in solidarity with others representing or working with our peer-led country or regional networks, and with HIV/Hepatitis organisations to promote this vital testing campaign.”